
Guggenheim lowered the firm’s price target on ArriVent Biopharma (AVBP) to $28 from $30 and keeps a Buy rating on the shares after the company reported Q3 results and provided
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | 10.52 | -9.83 | -48.30% |
| Name | Price | % Change | |
|---|---|---|---|
| $10.52 | -48.30% |

Guggenheim lowered the firm’s price target on ArriVent Biopharma (AVBP) to $28 from $30 and keeps a Buy rating on the shares after the company reported Q3 results and provided

Citi analyst Yigal Nochomovitz raised the firm’s price target on ArriVent Biopharma (AVBP) to $23 from $20 and keeps a Buy rating on the shares. Citi upped its probability of

Truist raised the firm’s price target on ArriVent Biopharma (AVBP) to $24 from $21 and keeps a Buy rating on the shares. The company’s Q3 update is repositioning-focused, following a

Analyst Jeet Mukherjee of BTIG maintained a Buy rating on ArriVent BioPharma, Inc., retaining the price target of $29.00. Jeet Mukherjee’s rating is based on several factors, including continued enrollment

ArriVent BioPharma, Inc. ( ($AVBP) ) has issued an update. On November 9, 2026, ArriVent reported third-quarter results and highlighted progress across its oncology pipeline. The company continued enrollment in

As of September 30, the company had cash and investments of $393.2M, which is expected to fund operations to mid-2028. “Enrollment remains on track for our global Phase 3 ALPACCA

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on ArriVent BioPharma, Inc. and keeping the price target at $27.00. Robert Burns has given his Buy rating due to

Guggenheim raised the firm’s price target on ArriVent Biopharma (AVBP) to $30 from $18 and keeps a Buy rating on the shares following presentation of first Phase 1 data on

Truist Financial analyst Supawat Thongthip has reiterated their bullish stance on AVBP stock, giving a Buy rating today. Supawat Thongthip has given his Buy rating due to a combination of

Truist analyst Supawat Thongthip raised the firm’s price target on ArriVent Biopharma (AVBP) to $21 from $18 and keeps a Buy rating on the shares. The firm views today’s 27%
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Oct 25, 2026 | ||||
| buy | Reiterated | Oct 20, 2026 | ||||
| buy | Reiterated | Oct 6, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 10, 2027TBA | $582.40M | $-0.98 | $0.00 | -0.07 | -2.87 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.